BNTX vs. ARGX, NBIX, TECH, BIIB, QGEN, RGEN, PCVX, EXEL, RVMD, and IBRX
Should you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include argenx (ARGX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Biogen (BIIB), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Exelixis (EXEL), Revolution Medicines (RVMD), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry.
BioNTech (NASDAQ:BNTX) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings.
15.5% of BioNTech shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 2.4% of argenx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
BioNTech has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.
BioNTech presently has a consensus target price of $117.25, indicating a potential upside of 26.10%. argenx has a consensus target price of $524.68, indicating a potential upside of 39.32%. Given argenx's stronger consensus rating and higher probable upside, analysts clearly believe argenx is more favorable than BioNTech.
In the previous week, argenx had 14 more articles in the media than BioNTech. MarketBeat recorded 34 mentions for argenx and 20 mentions for BioNTech. BioNTech's average media sentiment score of 0.96 beat argenx's score of 0.36 indicating that BioNTech is being referred to more favorably in the media.
BioNTech has a net margin of 4.01% compared to argenx's net margin of -22.58%. BioNTech's return on equity of 0.55% beat argenx's return on equity.
BioNTech has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.
argenx received 486 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 65.86% of users gave argenx an outperform vote while only 42.38% of users gave BioNTech an outperform vote.
Summary
argenx beats BioNTech on 10 of the 19 factors compared between the two stocks.
Get BioNTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioNTech Competitors List
Related Companies and Tools
